Y-mAbs Therapeutics A/SAktiv

Y-mAbs Therapeutics A/S is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel antibody therapeutic products to treat cancer.The Company's revenue comprise of external revenue associated with Naxitamab in Western Europe and service recharges to Y-mAbs Therapeutics Inc. in USA..

The income statement for 2025 shows a loss of DKK 38,462 thousand against a loss of DKK 12,500 thousand last year, and the balance sheet at 31 December 2025 shows a negative equity of DKK 163,652 thousand. During the 2025 financial year, the Company continued its activities in line with the Group’s strategic focus on the development and commercialisation of innovative treatments within oncology. The year was characterised by continued support of development programmes as well as adjustments to the organisation and use of resources in accordance with the Group’s priorities. Management considers the results for the year to be in line with expectations for the Company’s role and level of activity.In 2025, the Group was acquired by a new owner. In connection with the acquisition, the Group continued to progress its prioritised development and the commercialize the product DANYELZA. In addition, the year was characterised by organisational and corporate changes within the Group. These matters affected the planning and prioritisation of activities in the Danish entity, but did not change the Company’s overall purpose as a support function for the Group’s activities.Financial comfort and going concernThe parent company, Y-mAbs Therapeutics, Inc., has confirmed that it will continue to provide the necessary financial support in order for the Company to pay its obligations as they fall due by way of new loans or capital injections unless the Company has the means to do so.Loss of shar

Uddrag af ledelsesberetningen i den seneste årsrapport.